This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schoppet, M. Articles by Hofbauer, L. C. Search for Related Content PubMed PubMed Citation Articles by Schoppet, M. Articles by Hofbauer, L. C. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH

Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-B Ligand in Mönckeberg’s Sclerosis and Atherosclerosis

Departments of Internal Medicine and Cardiology (M.S., B.M.), Gastroenterology, Endocrinology and Metabolism (L.C.H.), and Pathology (P.J.B.), Philipps University, D-35033 Marburg, Germany; and Departments of Clinical Chemistry (N.A.-F., N.K.), Pathology (F.E.F.), and Biochemistry (K.T.P.), Justus Liebig University, D-35390 Giessen, Germany

Address all correspondence and requests for reprints to: Dr. Michael Schoppet, Department of Internal Medicine and Cardiology, Philipps University, Baldingerstrasse, D-35033 Marburg, Germany. E-mail: schoppet{at}mailer.uni-marburg.de.

Vascular calcification may occur at different areas of the vessel wall, including the intima in atherosclerosis and the media in Mönckeberg’s sclerosis. Medial calcification of arteries is common in patients with diabetes mellitus or chronic renal failure. Osteoprotegerin (OPG) and receptor activator of nuclear factor-B ligand are essential modulators of bone homeostasis and may be involved in the process of vascular calcification. In this study we investigated arteries from patients with Mönckeberg’s sclerosis and atherosclerosis. Apoptosis, which precedes vascular calcification in vitro, was assessed by an in situ ligation assay and was localized to the medial layer of arteries (Mönckeberg’s sclerosis) and the neointima (atherosclerosis). Immunohistochemistry and in situ hybridization revealed OPG immunoreactivity and mRNA expression surrounding calcified areas in the medial layer (Mönckeberg’s sclerosis), whereas OPG was mainly expressed adjacent to calcified neointimal lesions (atherosclerosis). Receptor activator of nuclear factor-B ligand protein and mRNA were barely or not detectable. Of note, TNF-related apoptosis-inducing ligand, an inducer of apoptosis that is also blocked by OPG, displayed a similar spatial distribution as OPG. In summary, we demonstrate enhanced apoptosis adjacent to vascular calcification, and the concurrent expression of regulators of apoptosis and osteoclastic differentiation, TNF-related apoptosis-inducing ligand and OPG, suggesting their involvement in the pathogenesis of vascular calcification.

This work was supported by a Heisenberg fellowship from the Deutsche Forschungsgemeinschaft (to L.C.H.; Ho 1875/3-1 and Ho 1875/4-1).

M.S. and N.A.-F. contributed equally to this work.

Abbreviations: DIG, Digoxigenin; DNase, deoxyribonuclease; EC, endothelial cells; ISL, in situ ligation assay; NBT/BCIP, nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-B; RANKL, RANK ligand; RNase, ribonuclease; SSC, sodium citrate buffer; TRAIL, TNF-related apoptosis-inducing ligand; VSMC, vascular smooth muscle cells.

This article has been cited by other articles:

				M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF]

				N. Koleganova, G. Piecha, E. Ritz, P. Schirmacher, A. Muller, H.-P. Meyer, and M.-L. Gross Arterial calcification in patients with chronic kidney disease Nephrol. Dial. Transplant., March 27, 2009; (2009) gfp137v1. [Abstract] [Full Text] [PDF]

				M. Nybo and L. M Rasmussen The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review Eur. J. Endocrinol., November 1, 2008; 159(5): 603 - 608. [Abstract] [Full Text] [PDF]

				P. A. McCullough, V. Agrawal, E. Danielewicz, and G. S. Abela Accelerated Atherosclerotic Calcification and Monckeberg's Sclerosis: A Continuum of Advanced Vascular Pathology in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1585 - 1598. [Abstract] [Full Text] [PDF]

				M. M. Kavurma, N. Y. Tan, and M. R. Bennett Death Receptors and Their Ligands in Atherosclerosis Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1694 - 1702. [Abstract] [Full Text] [PDF]

				L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				M. M. Kavurma, M. Schoppet, Y. V. Bobryshev, L. M. Khachigian, and M. R. Bennett TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-{kappa}B and Induction of Insulin-like Growth Factor-1 Receptor J. Biol. Chem., March 21, 2008; 283(12): 7754 - 7762. [Abstract] [Full Text] [PDF]

				S. Morony, Y. Tintut, Z. Zhang, R. C. Cattley, G. Van, D. Dwyer, M. Stolina, P. J. Kostenuik, and L. L. Demer Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr( / ) Mice Circulation, January 22, 2008; 117(3): 411 - 420. [Abstract] [Full Text] [PDF]

				D. Vega, N. M. Maalouf, and K. Sakhaee The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521. [Abstract] [Full Text] [PDF]

				S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF]

				A. Simionescu, D. T. Simionescu, and N. R. Vyavahare Osteogenic Responses in Fibroblasts Activated by Elastin Degradation Products and Transforming Growth Factor-{beta}1: Role of Myofibroblasts in Vascular Calcification Am. J. Pathol., July 1, 2007; 171(1): 116 - 123. [Abstract] [Full Text] [PDF]

				P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, B. Fabris, C. Celeghini, S. Capitani, and G. Zauli An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction Am. J. Pathol., December 1, 2006; 169(6): 2236 - 2244. [Abstract] [Full Text] [PDF]

				R. Westenfeld, M. Ketteler, and V. M. Brandenburg Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2075 - 2077. [Full Text] [PDF]

				X. Qin, M. A. Corriere, L. M. Matrisian, and R. J. Guzman Matrix Metalloproteinase Inhibition Attenuates Aortic Calcification Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1510 - 1516. [Abstract] [Full Text] [PDF]

				L. L. Demer and Y. Tintut Pitting Phosphate Transport Inhibitors Against Vascular Calcification Circ. Res., April 14, 2006; 98(7): 857 - 859. [Full Text] [PDF]

				W. J. Sandberg, A. Yndestad, E. Oie, C. Smith, T. Ueland, O. Ovchinnikova, A.-K. L. Robertson, F. Muller, A. G. Semb, H. Scholz, et al. Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 857 - 863. [Abstract] [Full Text] [PDF]

				L. M. Rasmussen, L. Tarnow, T. K. Hansen, H.-H. Parving, and A. Flyvbjerg Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients Eur. J. Endocrinol., January 1, 2006; 154(1): 75 - 81. [Abstract] [Full Text] [PDF]

				K. A. Hruska, S. Mathew, and G. Saab Bone Morphogenetic Proteins in Vascular Calcification Circ. Res., July 22, 2005; 97(2): 105 - 114. [Abstract] [Full Text] [PDF]

				B. A. Mosheimer, N. C. Kaneider, C. Feistritzer, A. M. Djanani, D. H. Sturn, J. R. Patsch, and C. J. Wiedermann Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2964 - 2971. [Abstract] [Full Text] [PDF]

				P. Collin-Osdoby Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin Circ. Res., November 26, 2004; 95(11): 1046 - 1057. [Abstract] [Full Text] [PDF]